Díaz-Cutraro, L, Verdaguer-Rodríguez, M, García-Mieres, H, Ferrer-Quintero, M, López-Carrilero, R, Palma-Sevillano, C, Lamarca, M, Espinosa, V, Barrigón, ML, González-Higueras, F, Pousa, E, Grasa, E, Lorente-Rovira, E, Gutiérrez-Zotes, A, Barajas, A, Ruiz-Delgado, I, Cid, J, Moritz, S, Rico, J, Sevilla-Llewellyn-Jones, J, Haro, JM, Ochoa, S
Sex-based differences in Jumping to Conclusions: a multidimensional analysis of first-episode psychosis
Alsina M, Villacampa G, de Andrea C, Vivancos A, Ponz-Sarvise M, Arrazubi V, Jimenez-Fonseca P, Diez M, Sanz-Garcia E, Martínez E, Guardeño R, Calvo M, Bugés C, Longo F, Navarro V, García-Galea E, Gros A, Ochoa MC, Lopez-Janeiro A, Sanchez-Gregorio S, Herrero C, Labiano I, Vila-Casadesús M, López D, Alexandru R, Muñoz S, Tabernero J, Melero I
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study.
Tomasello A, Moreu M, Terceño M, Dinia L, Barrena Caballo MR, Requena M, Jablonska M, Cendrero J, Flores A, Ortega S, Diana F, Henandez D, de Dios M, Rubiera M, Garcia-Tornel A, Rizzo F, Olivé M, Pérez-García C, Trejo Gallego C, Carmona T, Rodrigo-Gisbert M, Molina C, Ribo M
Randomized Study Comparing First-Line Dual Versus Single-Stent Retriever Technique: TWIN2WIN.
Rofes, P, Castillo-Manzano, C, Menéndez, M, Teulé, A, Iglesias, S, Munté, E, Ramos-Muntada, M, Gómez, C, Tornero, E, Darder, E, Montes, E, Valle, L, Capellá, G, Pineda, M, Brunet, J, Feliubadaló, L, del Valle, J, Lázaro, C
<i>TP53</i> germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes-González JF, Azaceta G, Ibañez M, Chen-Liang TH, Notario Mc Donnell C, Amer-Salas N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo Moreno JR, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M
AML typical mutations (CEBPA, FLT3, and NPM1) identify a high-risk CMML independent of CPSS-Mol classification.
Vener, C, Lillini, R, De Angelis, R, Bonfarnuzzo, S, Poirel, HA, Trama, A, Visser, O, Troussard, X, Marcos-Gragera, R, Maynadié, M, Demuru, E, Di Benedetto, C, Johannesen, TB, Solans, M, Paapsi, K, Guevara, M, Mousavi, SM, Blum, M, Von Moos, R, Bennett, D, Ragusa, R, Guilloteau, A, Mcshane, CM, Rossi, S, Sant, M
Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study
Pla H, Fullana B, Esteve A, Fort-Culillas R, Ferrando-Díez A, Fernández-Ortega A, Pous A, Stradella A, Villanueva-Vázquez R, Cirauqui B, Falo C, Martínez-Pérez E, Molina G, Del Barco S, Eraso A, Margelí M, Viñas G, Gil-Gil M, Petriz L, Pernas S
Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d'Oncologia Breast Cancer Observational Cohort Study.
Pérez-Lamas L, Segura Diaz A, García Delgado R, Álvarez-Larrán A, Senin MA, Mora E, Fox ML, Pastor Galan I, Azaceta G, Garrido Paniagua S, Pérez Lopez R, Trejos Carvajal DM, Angona A, Albo López C, Lorente Alegre P, Vara M, Vera Goñi JA, De Miguel Llorente D, Fernández Rodríguez Á, Marín Sanchez A, Hernando Megido A, Gómez Casares MT, Stuckey R, Carreño-Tarragona G, De Las Heras Rodriguez N, Xicoy B, Pérez Encinas M, Mata Serna R, Núñez Martin-Buitrago L, Ferrer Marín F, Amer Salas N, Guillén Rienda C, Velez P, Lamarca Eraso L, Martín S, Luts Khoroz I, De Cabo López E, Gil A, Martín-Consuegra Ramos S, Marco De Lucas F, Otero Martinez-Fornes MJ, Martín Mateos ML, Arquero T, Cabezudo Pérez E, López Gómez LA, Martínez Hellin Á, Tejedor A, Herrera de Pablo E, Mata Vazquez MI, Castillo Valero I, Fernández MJ, Aguilar C, Santaliestra M, García Menchon A, Navas Elorza B, Duran MA, Pérez Sala M, Hernández Santamaría T, Muñoz Jarreño MÁ, Dávila-Valls J, Torres Jiménez W, Gonzálvez Fernández JA, Torres Mantilla HA, Cobo Rodríguez T, Abuin Blanco A, Pérez F, Osorio Prendes S, Beneit Villena P, Peralta R, Herrera F, Cañamero Giro E, Jiménez Bárcenas R, Gasior Kabat M, González De Villambrosia S, Tercero-Mora Rodriguez MT, Menéndez Cuevas M, Cuevas Ruiz B, Fonseca-Santos M, Garcés Piquer S, De La Puerta R, Lorenzo Vizcaya Á, Hernández Boluda JC, García Gutiérrez V
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.
Thomas CE, Lin Y, Kim M, Kawaguchi ES, Qu C, Um CY, Lynch BM, Van Guelpen B, Tsilidis K, Carreras-Torres R, van Duijnhoven FJ, Sakoda LC, Campbell PT, Tian Y, Chang-Claude J, Bézieau S, Budiarto A, Palmer JR, Newcomb PA, Casey G, Le Marchand L, Giannakis M, Li CI, Gsur A, Newton C, Obón-Santacana M, Moreno V, Vodicka P, Brenner H, Hoffmeister M, Pellatt AJ, Schoen RE, Dimou N, Murphy N, Gunter MJ, Castellví-Bel S, Figueiredo JC, Chan AT, Song M, Li L, Bishop DT, Gruber SB, Baurley JW, Bien SA, Conti DV, Huyghe JR, Kundaje A, Su YR, Wang J, Keku TO, Woods MO, Berndt SI, Chanock SJ, Tangen CM, Wolk A, Burnett-Hartman A, Wu AH, White E, Devall MA, Díez-Obrero V, Drew DA, Giovannucci E, Hidaka A, Kim AE, Lewinger JP, Morrison J, Ose J, Papadimitriou N, Pardamean B, Peoples AR, Ruiz-Narvaez EA, Shcherbina A, Stern MC, Chen X, Thomas DC, Platz EA, Gauderman WJ, Peters U, Hsu L
Characterization of additive gene-environment interactions for colorectal cancer risk.
Bosch-Barrera J, Estévez-García P, Martín-Martorell P, Sabatier R, Nadal E, Sais E, Gascón P, Oaknin A, Rodon J, Lizcano JM, Muñoz-Guardiola P, Fierro-Durán G, Pedrós-Gámez O, Pérez-Montoyo H, Yeste-Velasco M, Cortal M, Pérez-Campos A, Alfón J, Domènech C, Morán T
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.
